ResMed (RMD)
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
$239.31-0.50%
Close 2026-11-05 · 1-day change
NYSEHealth CareMedical - Instruments & SuppliesSnapshot 2026-11-05
QuarterlyIQ Insights · RMD
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance is holding in the top half of its industry — the reason to own it looks intact.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 3.9% |
| Our one-year growth estimate | diamond | 4.8% |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-11-05.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Growth built into the price is above our model estimate.
The price assumes 0.9 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-11-05 · Compared with 14 industry peers · Company calendar date is not available
RMD — dividend update
Dated 2026-10-29
| Other Events. On October 29, 2026, we announced that our board of directors declared a quarterly cash dividend of US $0.66 per share. The dividend will have a record date of November 12, 2026, payable on December 17, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in Australian currency, ba…
Why it matters: Management kept its 5% to 7% core growth guide. Growth above 7% would beat that range.
Supportive ifA later report shows FY2027 core constant-currency revenue growth above 7%.
Worry ifA later report shows core revenue growth below 5% in constant currency, or management cuts its guide.
Why it matters: The latest margin gain came from productivity work. A further rise would show that progress continues.
Supportive ifA later quarter shows non-GAAP gross margin above 62.5% and year-over-year growth.
Worry ifA later quarter reports non-GAAP gross margin below 62.0%.
Why it matters: The sale helped fund over $1 billion in shareholder returns during Q1. Future cash flow will show how much came from the business itself.
Watch forA later quarter reports free cash flow of at least $374 million without MatrixCare sale proceeds.
Also watch forA later quarter reports free cash flow below $300 million without sale proceeds.
Why it matters: The new U.S. mask launch adds to a business that management linked to recent sales growth. Results can show if demand holds.
Supportive ifA later report says sleep masks and accessories grew year over year, with AirTouch F40 named as a driver.
Worry ifA later report says sleep masks and accessories fell year over year, or reports no launch contribution.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$115 on $10,000 · ±1.2% | How much price usually moves either way. |
| Bad day | $317 loss on $10,000 · 3.2% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,359 loss on $10,000 · 33.6% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: ResMed set a large annual target for dividends and share repurchases. Results show whether it reaches that goal.
Watch forCompany filings show FY2027 dividends and share buybacks total more than $1.85 billion.
Also watch forCompany filings show FY2027 dividends and share buybacks total $1.85 billion or less.